Introduction
Angiogenesis, the development of new blood vessels from pre-existing capillary networks, plays an important role in the development and progression of cancer (Folkman, 1990) . The induction of new blood vessels increases the opportunity for tumor cells to enter the circulation and metastasize (Liotta et al., 1974) . The extent of angiogenesis is frequently related to cancer progression and in some cases may predict the probability of metastasis (Srivastava et al., 1988; Weidner et al., 1991) . This linkage paved the way to clinical trials with antiangiogenic agents, which in some cases have dramatically changed the standards of care (Miller et al., 2005a, b; Motzer and Bukowski, 2006; Varker et al., 2007) . In particular, bevacuzimab/avastin, a humanized monoclonal-neutralizing antibody directed against vascular endothelial growth factor has since 2004 become incorporated into the first-line therapies in metastatic colorectal carcinoma (CRC) (Hurwitz et al., 2004) and other malignancies (Gasparini et al., 2005) . In addition to such targeted antiangiogenic agents designed to obliterate a well-defined molecular mechanism (for example, vascular endothelial growth factor/vascular endothelial growth factor receptor pathway), blood vessel inhibitory properties have also been uncovered in drugs with ostensibly unrelated activities, including cytotoxic anticancer chemotherapeutics (Browder et al., 2000; Klement et al., 2000) . Studies with cyclophosphamide and several other agents revealed that when administered at low but frequent (metronomic) doses, they selectively target growing endothelial cells and block formation of tumor blood vessels (Browder et al., 2000; Klement et al., 2000) .
In spite of the unquestionable successes of some of these antiangiogenic strategies, the responses of individual patients vary markedly (Kerbel and Folkman, 2002; Yang et al., 2003; Miller et al., 2005a, b) , in some instances amounting to overt resistance or lack of objective survival benefit (Jubb et al., 2006) . While there may be several reasons why a subset of cancer patients exhibit resistance to antiangiogenic agents, it has recently become apparent that this property may reside in the genetic make up of cancer cells (Rak et al., 2006) . For instance, oncogenic events such as loss of p53 tumor suppressor gene in CRC cells may render them refractory to ischemic conditions, that is, to the mechanism by which antiangiogenic agents exert their therapeutic influence (Yu et al., 2002) .
The natural gradients of oxygen, nutrients and pH caused by the limitations of tumor perfusion are thought to contribute to genetic alterations (Yuan and Glazer, 1998) and resistance to apoptosis (Galmarini and Galmarini, 2003) . In addition to various selective mechanisms (Rak et al., 1996; Yu et al., 2001 Yu et al., , 2002 , we have recently reported that the ischemic tumor microenvironment may actually induce de novo K-ras mutations in CRC cells, notably those with a defect in DNA mismatch repair (MMR) mechanisms (Shahrzad et al., 2005) . In this case, ischemic conditions downregulated one of the MMR proteins (MSH2) leading to an increase in frequency of K-ras mutations and eventual enrichment in mutant CRC cells (Shahrzad et al., 2005) . Mutant K-ras occurs in approximately half of all CRC cases, 75-100% of pancreatic cancers and almost 50% of lung adenocarcinomas (Minamoto et al., 2002) , and is associated with chemoresistance and radioresistance (Bernhard et al., 2000; Perona and Sa´nchez-Pe´rez, 2004) , and the angiogenic phenotype (Rak et al., 1995) . K-ras proto-oncogene becomes activated through a single-point mutation in one of the three critical codons 12, 13 or 61 (Bos, 1989) . This renders the gene vulnerable to a defective MMR mechanism, which is involved in removing base mismatches that may occur spontaneously, or as a result of therapeutically induced DNA mutagenesis (Jiricny, 1998) .
We reasoned that an important context in which the aforementioned ischemic mechanisms may lead to increased K-ras mutagenesis is, in fact, during the course of antiangiogenic therapy. While moderate inhibition of aberrant growth of the tumor-associated vasculature may in some cases lead to transient improvement of tumor perfusion (Jain, 2005) , a more complete therapeutic obliteration of this network implicitly brings about a state of ischemia, which may become lethal to some but not all cancer cells. It follows that such surviving cells may have pre-existing or acquired oncogenic alterations. Here we show that, indeed, xenografts of MMR-deficient CRC cells exposed to metronomic treatment with cyclophosphamide exhibit an increased frequency of K-ras mutations. These mutations were not recapitulated in vitro by treatment of these cells with an activated 4-hydroxy form of cyclophosphamide. We propose that the unappreciated consequences of antiangiogenic treatment may include an accelerated genetic progression of tumors with certain MMR defects.
Results
Accelerated tumor growth post-metronomic (LDM) therapy Dks-8 cells are K-ras wt/null (Shirasawa et al., 1993) , microsatellite unstable and deficient for the MMR enzyme MSH6 (Boyer et al., 1995) . While originally reported to be non-tumorigenic (Shirasawa et al., 1993) in our hands these cells demonstrate attenuated tumorigenicity (Shahrzad et al., 2005) , and in this study formed palpable tumors in all mice 45 days after subcutaneous injection of 2 Â 10 6 cells into the right flank of RAG-1 null mice. When the average tumor size reached 35 mm 3 mice were randomized into treatment and control groups and subjected to low-dose (metronomic) cyclophosphamide (LDM) for a period of 2 weeks followed by a 2-week break period. This study was performed in two similar trials; there were no statistically significant differences for the same treatment between trials, and so growth rates were calculated using pooled data from both trials. Growth rates of control and cyclophosphamide-treated tumors (N ¼ 10 for each group) were not significantly different during the 2-week period of LDM treatment, but there was a significant suppression of Dks-8 xenograft growth during the first week post-treatment (Po0.05; Figure 1) . Surprisingly, the LDM-treated tumors displayed accelerated rates of growth approximately 1 week after cessation of drug exposure. Eventually, these tumors reached and then significantly exceeded the sizes of their control counterparts (Po0.05; Figure 1 ).
LDM-induced tumor hypoxia
To assess the effects of the LDM treatment at the microscopic level, we analyzed the extent of tumor hypoxia and microvessel density (MVD; number of blood vessels per mm 2 ). Hypoxic areas, as determined by immunostaining for Hypoxyprobe-1 protein adducts, were wider and more extensive in the xenografts treated with LDM cyclophosphamide compared to controls (Figures 2a and b) . LDM cyclophosphamide treatment increased the hypoxic area in Dks-8 xenografts by 170% on average, a difference that was statistically significant (Po0.05; Figure 2c ). To confirm the antiangiogenic ) from Dks-8 xenografts. Significant differences between groups were seen on days 97 and 105 after injection of Dks-8 cells (N ¼ 10 for each group; *Po0.05), initially leading to tumor stasis (day 97; 1 week after cessation of treatment) and then to significant increase in tumor size in treated mice (day 105; that is, 2 weeks after cessation of treatment) compared to controls.
Antiangiogenic treatment and K-ras mutation S Shahrzad et al action of LDM cyclophosphamide, MVD was scored in tumors by quantifying CD31 immunostained microvessels in control and treated tumors (Figures 2d and e) . All microvessels were counted per tumor section, and there was a statistically significant 2.5-fold reduction in MVD in LDM cyclophosphamide-treated xenografts compared to control (Figure 2f ; Po0.05). These differences in tumor hypoxia and MVD were still detected 2 weeks after cessation of LDM cyclophosphamide treatment, highlighting the potent blockade of neovascularization induced by this approach.
Changes in the K-ras status in LDM-treated tumors Despite the successful reduction in MVD and concomitant increased hypoxia seen with LDM cyclophosphamide, treated tumors displayed highly accelerated Antiangiogenic treatment and K-ras mutation S Shahrzad et al growth compared to control tumors in the 2-week period after cessation of therapy. Since we had previously shown that K-ras wt/null Dks-8 xenografts develop mutations in codon 13 of this oncogene (Shahrzad et al., 2005) , we explored the possibility that this event may have been enhanced in treated tumors. As expected, the Dks-8 cell line was K-ras wt/null at codon 13. K-ras mutation in Dks-8 tumors was barely detectable using the single-step PCR-restriction fragment length polymorphism (RFLP) method in all tumor pieces (data not shown), but clear evidence of K-ras mutation was apparent when the two-step PCR-RFLP was employed. Control tumors showed some mutation and all LDM cyclophosphamide-treated tumors showed considerable enrichment for mutation at codon 13 compared to control tumors ( Figure 3 ). Densitometry of fragments of size 165 bp of xenografts of cyclophosphamide-treated mice (N ¼ 10) in comparison with that of the control xenografts (N ¼ 10) provided semiquantitative values for the presence of mutant K-ras codon 13. Xenografts of the treated mice had threefold stronger bands at 165 bp compared to the controls. Amplified product was extracted from the agarose gels and sequenced as described above. Only transition mutations of the second base of codon 13 (GGC -GAC; glycine -aspartic acid) were found in all DNA extracted from undigested bands of those cells. Thus, a rapid accumulation of mutant cells was facilitated in tumors exposed to LDM-induced hypoxia. Using similar PCR-RFLP approaches (modified from Toyooka et al., 2003; Shahrzad et al., 2005) , we further examined K-ras mutations at codon 61 in the xenografts. We found no evidence for de novo development of mutation at this additional codon in either control or treatment group of the xenografted tumors (Supplementary Figure 1 ). To originally generate the K-ras wt/null cell line Dks-8, DLD-1 mutant K-ras was selectively disrupted by homologous recombination, a method that interferes with the detection of de novo development of mutation at codon 12 (Shirasawa et al., 1993) ; thus we could not test the xenografts for changes at this codon.
Nevertheless, this study does not intend to exclude the possibility of additional K-ras mutations at codon 12 in MMR-deficient cell lines due to ischemic conditions of the tumor microenvironment.
Isolation of tumor cells harboring mutant K-ras oncogene from hypoxic tumor regions We postulated that cells harboring mutant K-ras occupy hypoxic regions of tumors and thereby could be isolated by using previously described cell sorting according to the gradient of Hoechst 33342 (Herman et al., 1989; Yu et al., 2002) . Indeed, the Hoechst 33342 injection highlighted a highly fluorescent population of cells immediately surrounding the perfused vasculature. In contrast, weakly fluorescent cells were mainly derived from tumor regions more distal to the perfused blood vessels (Herman et al., 1989; Yu et al., 2002) (Figure 4a ). Immunofluorescence staining of the sorted cells for hypoxic protein adducts indicated that those displaying the dimmest Hoechst fluorescence contained abundant hypoxic protein adducts, while cells with the brightest Hoechst fluorescence were negative in this regard . This confirms that there is an inverse relationship between Hoechst staining intensity and the hypoxic status of cells sorted from our Dks-8 xenografts. We employed the two-step PCR-RFLP for selective amplification of the K-ras codon 13 mutation (as described above) on DNA obtained from our sorted cells. Little or no K-ras mutation was found in the DNA obtained from 'Bright' (normoxic) cells, however, the 'Dim' (hypoxic) cells demonstrated a clear band (165 bp) for codon 13 mutation, represented by a 165 bp amplicon (Figure 4f ). Sequencing of these products revealed them to be transition mutations of the second base of codon 13 (GGC -GAC; glycine -aspartic acid). The detection limit of this two-step PCR-RFLP assay is one in 2 Â 10 6 cells (as determined by serial dilutions of K-ras mutant (DLD-1) in wild-type cells (Dks-8); data not shown (Shahrzad et al., 2005) ). This confirms that the K-ras G13D mutation identified in DNA from whole xenografts primarily occurred in hypoxic cells.
Unchanged K-ras status in tumor cells exposed to mafosfamide in vitro To investigate whether direct interaction of cyclophosphamide with the cancer cell genome, for instance, as an alkylating agent, could be the cause of increased K-ras mutations observed in the LDM-treated mice, we employed an activated form of cyclophosphamide, mafosfamide (Takamizawa et al., 1975; Yu and Waxman, 1996) . Dks-8 cells were incubated with the drug in culture and assayed for the rate of K-ras mutations. While we found cytotoxic effects of the drug at high concentrations (0.1 and 0.2 mg ml À1 ), none of the incubations (that is, at 0.002, 0.02, 0.1 and 0.2 mg ml À1 final concentration for up to 2 weeks) resulted in the development of detectable K-ras mutations, even after 2 weeks of recovery ( Figure 5 ). These results suggest that the increased K-ras mutation observed 165 bp 137 bp C1 C2 C3 C4 T1 T2 T3 T4
Dks-8 DLD-1 water Figure 3 Two-step PCR-restriction fragment length polymorphism analysis of DNA from Dks-8 xenografts of low-dose metronomic cyclophosphamide-treated mice (T) versus control mice (C) was used to detect K-ras mutations at codon 13. Wildtype DNA produces a 137 bp band, and mutant DNA produces a 165 bp product. All 10 treated tumors had enhanced mutant K-ras compared to the low but detectable levels of mutant oncogene as seen in control tumors (four examples are shown). Cultured DLD-1 cells were used as positive control for K-ras codon 13 mutation, and Dks-8 cells as positive control for K-ras wild-type DNA.
Antiangiogenic treatment and K-ras mutation S Shahrzad et al upon exposure to LDM in vivo were not the result of a direct mutagenic or cytotoxic effect of cyclophosphamide, but rather originated from indirect effects of the drug, notably angiogenesis inhibition and concomitant hypoxia.
Discussion
Despite effective angiogenic blockade, increased tumor progression has previously been reported in xenograft studies of experimental tumor growth (Klement et al., 2000; Emmenegger et al., 2006) . These observations, together with the results of clinical trials using antiangiogenic agents (Yang et al., 2003; Hurwitz et al., 2004; Miller et al., 2005a, b; Motzer and Bukowski, 2006; Varker et al., 2007) suggest a more complex impact of this treatment modality than previously anticipated. In most current clinical studies, antiangiogenic agents are used as adjuvant therapy in combination with chemotherapy or sometimes chemoradiotherapy. However, the relationship between Antiangiogenic treatment and K-ras mutation S Shahrzad et al angiogenesis and tumor progression emerges as increasingly multifaceted. For instance, there are conflicting data regarding the influence of extensive vascularization on tumor progression (Koukourakis et al., 2000) , and intriguing evidence that antiangiogenic therapy may paradoxically enhance the efficacy of standard cytotoxic approaches (Kerbel, 2006) . Tumor progression may be promoted by both chronic (diffusion-limited) as well as acute (fluctuating) tumor hypoxia (Janssen et al., 2005; Rofstad et al., 2007) , and antiangiogenic therapy increases the proportion of cells undergoing both types of hypoxia (Rofstad et al., 2007) . Currently, intervention with antiangiogenic agents is performed in relatively late stages of disease, where there are more angiogenic and survival pathways involved and manipulations of any single factor (such as inhibition of vascular endothelial growth factor) likely become less critical for cancer progression Kerbel and Folkman, 2002; Franco et al., 2006) . Interestingly, addition of bevacizumab to first-line chemotherapy in patients with metastatic colorectal cancer increased response rates and prolonged overall survival (Hurwitz et al., 2004) . Nevertheless, the response to these drugs varied significantly among patients, and in all studies performed to date numerous patients underwent an antiangiogenic regimen without apparent significant benefit in survival or time to progression (Yang et al., 2003; Miller et al., 2005a, b; Motzer and Bukowski, 2006; Varker et al., 2007) . Therefore, it is important that we understand the causes of this variable drug response and discover the molecular indicators of individual response to antiangiogenic therapy to select an optimal regimen for each individual. Redundancy of angiogenic molecules and/or transient upregulation of endothelial survival factors , differing vascular dependence of cancer cells , and differing cancer cell characteristics, especially with regard to oncogene activation and tumor suppressor inactivation status (Yu et al., 2002) , may account for the major causes of differential response to antiangiogenic approaches seen to date. The latter issue has been the focus of our study.
We previously demonstrated that tumor progression is related to selection of cells with reduced vascular dependence , which may be one of the important mechanisms involved in tumor progression in the face of effective angiogenic blockade. We had previously shown that although inactivation of mutant K-ras in MMR-defective colorectal Dks-8 cells led to significantly diminished in vivo growth capacity, tumors eventually developed with a latency period of more than 30 days, and subsequently grew slowly. We showed that some of those cells had acquired a secondary mutation in the remaining K-ras allele in the tumor microenvironment (Shahrzad et al., 2005) . Similar to those results, in this study we also detected the induction of K-ras mutation due to ischemic conditions found in tumors, and further confirmed that these mutations are primarily arising in hypoxic cells. Treatment of xenografts with LDM cyclophosphamide led to increased hypoxia and decreased MVD, which could explain the considerable increase in K-ras mutation that we also detected in these treated tumors. K-ras mutations result in production of constitutively activated K-ras proteins and continual transmission of signals allowing improper cell proliferation (Bos, 1989) , and hence accelerated tumor growth. The effect of LDM cyclophosphamide treatment on K-ras mutation supports our previous finding that antiangiogenic therapies may lead to selection of hypoxia-resistant tumor cells as one mechanism of 'resistance' (Yu et al., 2002) .
The system employed in this study uses a MMRdeficient CRC cell line that has been artificially engineered to disrupt a previously mutant K-ras allele (Shirasawa et al., 1993) . Since K-ras mutation is known to lead to other alterations in cancer cell behavior contributing to tumor progression (notably uncontrolled proliferation and enhanced production of angiogenic factors; Bos, 1989; Rak et al., 1995) , it is possible that CRC cells that were always wild type for K-ras may behave differently under similar experimental conditions. Interestingly, the parental cells for this Dks-8 line (DLD-1 cells, which have one allele mutated) also show increased K-ras mutation upon exposure to ischemic conditions in vitro and in vivo (Supplementary Figure 2 and Shahrzad et al., 2005) , suggesting that the mutagenic capacity of these cells is similar to their Dks-8 counterparts. Investigation of the factors affecting de novo K-ras mutations in other CRC cell lines wild type for this oncogene, and of the influence ischemia may have on the evolution of K-ras mutations in CRC patients receiving antiangiogenic therapy, are areas of investigation currently underway in our laboratory.
Hereditary nonpolyposis colorectal cancer syndrome is caused by a germline mutation in a DNA MMR gene, most commonly affecting the genes MLH1 (40%), MSH2 (50%) and/or MSH6 (10%) (Mitchell et al., 2002; Peltomaki and Vasen, 2004) . Individuals with . Fragments of size 165 bp represent mutated K-ras codon, and fragments of size 137 bp represent wild type. The active metabolite of cyclophosphamide did not lead to K-ras mutation in cultured Dks-8 cells after 2 weeks treatment, or after an additional 2-week recovery time in vitro without mafosfamide (data not shown). DNA from DLD-1 cells was used as positive control for mutant K-ras.
Antiangiogenic treatment and K-ras mutation S Shahrzad et al hereditary nonpolyposis colorectal cancer are at increased risk for several types of cancer, with the highest life-time risks for CRC (80%), endometrial cancer (40-60%), ovarian cancer (10-15%), cancer of the small intestine and upper urothelial cancer (Aarnio et al., 1999) . In addition, somatic MMR defects occur in a subset of certain sporadic tumor types, for example, in 15-20% of gastrointestinal and endometrial cancer, which are mostly caused by somatic hypermethylation of the MLH1 promoter (Kane et al., 1997; Esteller et al., 1998) . Cancers with defective MMR system may be considered susceptible to hypoxia-mediated K-ras mutation. Over 95% of hereditary nonpolyposis colorectal cancer tumors can be characterized by widespread microsatellite instability and 90% by loss of immunohistochemical expression of the MMR protein affected (Halvarsson et al., 2004) . Accurately predicting the effects of antiangiogenic therapy on different cancers is important for the selection of optimal treatment strategies and regimens. Our results suggest that identifying individuals who are susceptible for development of hypoxia-mediated K-ras mutation might be a useful addition to the clinical diagnosis of colorectal cancer. Thus, patients presenting with tumors still wild type for K-ras but with impaired MMR may benefit from a different therapeutic regime than those whose tumors are already K-ras mutant. One possibility might be to combine antiangiogenic approaches with hypoxic cell cytotoxins, a new class of drugs that specifically target hypoxic cells (Brown, 2000; Brown and Wilson, 2004) , to reduce the incidence of K-ras mutagenesis and its concomitant effects on tumor progression during antiangiogenic therapy.
Materials and methods
Abbreviated Materials and methods are presented here; full detailed descriptions of additional methods and materials are located in Supplementary Materials.
Cell lines
The human DLD-1 CRC cell line (Dexter et al., 1981) harbors one mutant K-ras G13D allele, and was obtained from the American Type Culture Collection. DLD-1 K-ras G13D was selectively disrupted by homologous recombination to generate the K-ras wt/null cell line Dks-8 (Shirasawa et al., 1993) . Both DLD-1 and Dks-8 cells are microsatellite-unstable and deficient for the MMR enzyme MSH6 (Boyer et al., 1995) . Cells were maintained in standard culture conditions: DMEM (Sigma, Oakville, ON, Canada) supplemented with 10% heatinactivated fetal bovine serum, 50 mg ml À1 gentamicin, 1 mM sodium pyruvate and 1.25 mg ml À1 amphotericin B as 5 ml ml
À1
of fungizone antimycotic (Invitrogen/Gibco, Burlington, ON, Canada). Cells were cultured at 37 1C in a humidified atmosphere containing 5% CO 2 . To exclude the possibility that these knockout cells were contaminated by rare spontaneous reversion K-ras mutants, a monoclonal Dks-8 cell population was obtained by dilution cloning, and the wild-type K-ras allele was confirmed by two-step PCR-RFLP. Each experiment in this study was performed with freshly expanded cells from cryopreserved stock of this clone, and K-ras status was confirmed as wild type by two-step PCR-RFLP of cells used in each experiment (xenograft production and in vitro exposures).
Cyclophosphamide trial
All in vivo procedures were performed according to the guidelines and recommendations of the Canadian Council of Animal Care (CCAC), and approved by the University of Guelph local Animal Care Committee. The study was performed in two independent trials. We established xenograft tumors by injecting 2 Â 10 6 Dks-8 cells into the right flank of RAG-1 null mice (Chen et al., 1994) . Tumor growth was assessed by caliper measurements every 3-4 days, and tumor size was calculated using the equation: volume ¼ length Â width 2 Â 0.5 (Shahrzad et al., 2005) . When the average tumor size reached 35 mm 3 (76 days) for this slow-growing, poorly tumorigenic cell line (Shahrzad et al., 2005) , mice were randomly allocated into two groups: treatment and control. In the first trial there were four (N ¼ 4) mice in each group, and in the second trial there were six mice (N ¼ 6). For the treated group, mice were given drinking water with 200 mg ml
À1
, a dose of approximately 30 mg kg À1 day
, of cyclophosphamide (Sigma) for 2 weeks (water was replaced twice weekly; control mice received normal drinking water). After 2 weeks, the treatment was discontinued, and both groups of mice were kept for an additional 2 weeks under standard husbandry conditions. At the end of this second 2-week period, mice received intraperitoneal injection of Hypoxyprobe (150 mg kg
; Calbiochem/ VWR, Mississaga, ON, Canada) 1 h prior to euthanasia, and intravenous injection of Hoechst 3342 dye (0.25 mg per mouse; Sigma) 5 min prior to euthanasia. Mice were euthanized by CO 2 asphyxia followed by cervical dislocation. Tumors were removed from the mice and cut into small pieces, which were snap-frozen in cryomatrix and stored at À80 1C for later sectioning or snap-frozen and stored at À80 1C for subsequent DNA isolation.
Hypoxia measurements
Cryosections of tumor xenografts were fixed in 4% paraformaldehyde, and immunostained for hypoxic adducts using anti-Hypoxyprobe-1 followed by biotin-conjugated goat antimouse for 3-amino-9-ethyl-carbazole histochemistry. Slides were coded and scored in a semiblinded manner, and the areas of hypoxia were scored and assessed by Optimas 6.2 image analysis software (MediaCybernetics, San Diego, CA, USA). The total hypoxic area for each section was divided by the cross-sectional area to obtain the proportion of hypoxia in each tumor.
Blood vessel density
The vessels in the tumor tissues were stained using an antibody to the endothelial marker CD31 (DeLisser et al., 1997) with rat anti-mouse CD31 primary antibody (PECAM-1) and donkey anti-rat Alexa Fluor 546-conjugated secondary antibody; nuclei were counterstained with 4,6-diamidino-2-phenylindole. Slides were coded and scored in a semiblinded manner and the total number of blood vessels for each section was divided by the cross-sectional area to obtain the MVD (number of blood vessels per mm 2 ).
Cell sorting
We used our previously reported approach to sort cells from Dks-8 xenografts based on their proximity to perfused blood vessels (Herman et al., 1989; Yu et al., 2002) . Briefly, the cells most proximal to perfused vessels were labeled by cardiac injection of 0.25 mg per mouse Hoechst 33342 dye, in 200 ml volume, 5 min before euthanasia. After enzymatic disaggregation of each Dks-8 xenograft into a single-cell suspension, samples were fixed in 10% formalin and sorted by fluorescence-activated cell sorting (using a 350-70 nm UV channel with a FACSVantageSE instrument); five Dks-8 xenografts were used for this part of the study. Sorted cells were stained with anti-Hypoxyprobe-1 antibody and secondary anti-mouse Cy3. The slides were washed and mounted using a fluorescent mounting medium (DakoCytomation, Mississaga, ON, Canada). Remaining sorted cells were pelletted and their DNA was extracted for K-ras mutation analysis.
In vitro exposure to cyclophosphamide (mafosfamide) To investigate whether the direct DNA alkylating action of cyclophosphamide plays a role in mutation of the K-ras gene, Dks-8 cells were exposed to a broad range of concentrations in vitro (0.002, 0.02, 0.1 and 0.2 mg ml À1 final concentration). Cyclophosphamide must be metabolically converted into the active 4-hydroxylated intermediate by liver microsomal mono-oxygenases to exert its effects (Chang et al., 1993; Yu and Waxman, 1996; Ren et al., 1997) . The 4-hydroperoxycyclophosphamide is a preactivated derivative of cyclophosphamide that hydrolyzes spontaneously in aqueous solution to form 4-hydroxycyclophosphamide. Mafosfamide (D-17272, NIOMECH, IIT GmbH, Bielefeld, NRW, Germany) is a cyclophosphamide derivative that rapidly generates 4-hydroperoxycyclophosphamide after aqueous dissolution (Takamizawa et al., 1975; Zon et al., 1984) .
Dks-8 cells were seeded into 100 mm plates at a density of 1 Â 10 6 cells per plate, and incubated under standard conditions overnight. Thereafter, six plates were assigned to each of two groups-control, and drug treatment-and the cells received fresh media with mafosfamide every 3 days for 2 weeks. After mafosfamide treatment, three plates from each group were trypsinized, and cells were washed twice using a large volume of phosphate-buffered saline; washed cell pellets were kept at À80 1C until DNA isolation. The remaining plates were passaged and seeded at 1 Â 10 6 cells per 100 mm plate, cultured under standard conditions in drug-free media for an additional 2 weeks, then harvested as described above. Each experiment was repeated at least twice; the results for the samples exposed to each condition were compared with each other, and with those of simultaneous control (no mafosfamide) samples.
K-ras mutation analysis DNA from DLD-1 cells, which are heterozygously mutated in codon 13 (Shirasawa et al., 1993) were used as a positive control for codon 13 K-ras mutation. DNA was extracted from cultured cells and xenografted tissues, and K-ras mutation status at codon 13 and 61 was determined as described (Toyooka et al., 2003; Shahrzad et al., 2005) . For codon 13, if there is a mutation in either of the first two bases, the mutant PCR fragment will not be cut by XcmI, and will remain at its original size of 165 bp. To enhance the 165 bp products, which represent the mutated DNA, a second PCR-RFLP using the products of the first digestion as templates was performed. The same primers from the first PCR could thus more selectively amplify the undigested mutated DNA from the first digestion. Mutated K-ras was confirmed and identified by sequencing. K-ras codon 61 letter 1 and 2 mutations were determined by a two-step PCR-RFLP analysis, and letter 3 mutations were determined by a singlestep PCR-RFLP (modified from Toyooka et al., 2003; Shahrzad et al., 2005) .
Statistical analysis
Quantitative data are presented as means of several independent measurements±s.d. Statistical analysis (t-test) was used to determine differences between means within experiments, with a two-tailed level of significance (Po0.05).
